An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects with X-linked Retinitis Pigmentosa caused by RPGR-ORF15 mutations (20172166)
Study Description
Phase IIa/b trial for gene therapy in X-linked Retinitis Pigmentosa
Eligibility Summary
not enrolling
Investigators
- Sandeep Grover, M.D.
Ophthalmology